Herantis Pharma Oyj
OMXH:HRTIS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.2
1.855
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Herantis Pharma Oyj
Total Current Liabilities
Herantis Pharma Oyj
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Herantis Pharma Oyj
OMXH:HRTIS
|
Total Current Liabilities
€1.6m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
O
|
Orion Oyj
OMXH:ORNBV
|
Total Current Liabilities
€349.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
Herantis Pharma Oyj
Glance View
Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.
See Also
What is Herantis Pharma Oyj's Total Current Liabilities?
Total Current Liabilities
1.6m
EUR
Based on the financial report for Jun 30, 2024, Herantis Pharma Oyj's Total Current Liabilities amounts to 1.6m EUR.
What is Herantis Pharma Oyj's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
9%
Over the last year, the Total Current Liabilities growth was -42%. The average annual Total Current Liabilities growth rates for Herantis Pharma Oyj have been -33% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
